bluuebunny/crossref_metadata_2025_split huggingface dataset:
Clinical determinants of blood biomarkers of atrial cardiomyopathy: results from the ISOLATION AF ablation cohort study
Authors: Habibi Z , Verhaert D V M , Hermans B J M , Philippens S A M , Westra S W , Chaldoupi S M , Maesen B A E , Isaacs A , Zeemering S , Linz D , Vernooy K , Schotten U 
Published: May 2024

Abstract

Background
In patients with atrial fibrillation (AF), significant advances have been made in identifying biomarkers representing diverse pathophysiological pathways, such as inflammation, myocyte injury, collagen deposition, and fatty-fibrotic infiltration. Data on clinical determinants of biomarkers in patients with AF, however, are lacking.

Objective
Our primary aim was to explore the relationships between clinical determinants and biomarker levels in AF patients scheduled for catheter ablation.

Methods
A cross-sectional analysis was conducted in AF patients undergoing catheter ablation included in the prospective multicenter ISOLATION study between July 2020 and May 2022. Clinical characteristics, routine tests and blood samples were collected before ablation. Blood samples were analyzed for known and novel cardiovascular biomarkers, including Bone morphogenetic protein 10 (BMP10), Angiopoietin-2 (Ang-2), Fibroblast growth factor 23 (FGF-23), Dickkopf-related protein 3 (DKK-3), Endocan (ESM-1), Insulin-like growth factor-binding protein 7 (IGFBP-7), B-type natriuretic peptides (proBNP, NTproBNP), High sensitive Troponin-T (hsTnT)&lt; Growth differentiation factor 15 (GDF-15), interleukin 6 (IL-6), Fatty acid binding protein 3 (FABP3), Cancer antigen-125 (Ca-125) (Table 1). For each biomarker we trained a lasso regression model to identify the most important clinical determinants out of all the 60 available determinants (including anthropometry, ECG, comorbidities). The strongest associations are summarized in figure 1.

Results
Blood samples of 508 patients were analyzed. The mean age was 63 ±9 years, and 31.1% were female. 354 patients (69.7%) had paroxysmal AF and 154 patients (30.3%) had persistent AF. Heart failure was reported in 77 patients (15.2%). 355 (72.3%) patients were in sinus rhythm during sample collection. The following clinical determinants of biomarker levels were frequently identified as important: rhythm during blood phlebotomy, age, heart failure, decreased kidney function and female sex (Figure 1). Most notably, rhythm at the time of sampling was strongly associated with various biomarker levels. Female sex was positively associated with BMP10 and FGF23 (atrial fibrosis), but negatively associated with hsTNT (cardiac injury).

Conclusion
In patients with AF scheduled for catheter ablation, we identified several clinical determinants of biomarker levels with potential implications for disease mechanisms. In women, pro-fibrotic biomarkers were frequently higher, while male patients more often showed signs of myocardial injury. Importantly, rhythm during blood draw is a very strong determinant of many biomarkers and should be taken into account in future biomarker studies.Figure 1.Table 1.
Investigating the relationship between the leukocyte telomere length and the incidence of atrial fibrillation: a study utilizing data from the UK Biobank
Authors: Kim H J , Yang P S , Kim D H , Sung J H , Jang E S , Yu H T , Kim T H , Pak H N , Lee M H , Joung B Y 
Published: May 2024

Abstract

Background
Atrial fibrillation (AF) is a common cardiac arrhythmia linked to a higher risk of stroke, heart failure, and death. Telomeres are DNA-protein complexes located at the end of chromosomes, and telomere length is known to be associated with biological aging and age-related disease. However, the relationship between leukocyte telomere length (LTL) and AF has been inconsistent in the literature. This study aims to clarify the relationship between LTL and AF risk using UK Biobank data and to examine the link between AF and both biological and chronological aging.

Methods
The UK Biobank cohort of 502,421 participants aged 40-70 was recruited across 22 UK centers from 2006-2010. After excluding i) missing values (n=32,219), ii) previous AF history (n=6,746) and iii) valvular heart disease (n=3,204), a total of 460,252 participants without AF (median age, 58.0 [interquartile range (IQR), 50.0–64.0] years; 208,543 [45.3%] male) were included. Participants were categorized into four groups based on the LTL, as determined by the adjusted T/S ratio from whole blood test. To investigate the intermediate phenotype prior to the onset of atrial fibrillation, we compared each group with LA maximum volume, LA minimum volume, LA stroke volume, and LA ejection fraction. Throughout the follow-up period, new-onset atrial fibrillation was documented. Survival analysis was conducted using Kaplan-Meier analysis and Cox proportional regression analysis.

Results
Among 460,252 participants without AF, the new-onset AF group had more comorbidities and lower mean LTL. Groups with shorter LTL tend to be older, and new-onset AF is more prevalent in these groups. Additionally, the incidence of comorbidities is generally higher in the groups with shorter LTL. It was observed that as the LTL shortens, the LA stroke volume decreases. The Kaplan-Meier curve demonstrated that shorter LTL correlated with increased new-onset AF risk. (Log-rank P &lt; 0.001) However, upon examination through a multivariable univariate Cox proportional regression analysis, telomere length did not show as an independent risk factor for new-onset AF. (aHR 1.00, 95% CI 1.00-1.00, P=0.099, Adjusted T/S ratio).

Conclusion
Even though the incidence of AF increased as LTL shortened, there was no relationship between LTL and new-onset AF when the covariate was adjusted.
Left atrial low-voltage areas, but not volume, predict the recurrence of atrial fibrillation in repeat ablation procedures
Authors: Georgi C , Bannehr M , Lochmann M , Reiners D , Haase-Fielitz A , Seifert M , Butter C 
Published: May 2024

Abstract

Background
Left atrial (LA) low voltage areas (LVA) are a controversial target in atrial fibrillation ablation procedures. However, LVA and LA volume are good predictors of arrhythmia recurrence in ablation-naïve patients. Their predictive value in pre-ablated, myopathic atria is uncertain.

Purpose
Patient selection for repeat ablations is sometimes difficult. Predicting factors of rhythm outcome might help with the decision.

Methods
Consecutive patients with recurrent atrial fibrillation (AF) or atrial tachycardia (AT) scheduled for repeat LA ablation were included in the prospective Bernau ablation registry between 2016 and 2020. All patients received a complete LA ultra-high-density map before ablation. Maps were analyzed for LA size, LVA percentage and distribution. The predictive value of demographic, anatomic and mapping variables on AF recurrence was analyzed in univariate logistic regression and integrated in a multivariate Cox regression if the p-value was &lt;0.250.

Results
160 patients (50.6% male, 1.3 pre-ablations, 60% persistent AF) with complete LA voltage maps were included. Mean follow-up time was 16 ± 11 months. Mean recorded electrograms (EGMs) per map were 9754 ± 5808, mean LA volume was 176.1 ± 35.9 ml and mean rate of LVAs &lt; 0.5 mV was 30.6% ± 23.1%. Baseline characteristics are depicted in table 1. During follow-up recurrence rate of AF or AT &gt; 30 seconds was 55.6%. Patients with recurrence had a significant higher percentage of LVAs (40.0% vs. 18.8%, p&lt;.001) but no relevant difference in LA volume (172 vs. 178 ml, p=.299). ROC curves revealed a cut-off of 22% LVAs with highest sensitivity (73.0%) and specificity (71.8%). Based on this cut-off event free survival was significantly higher in the Low LVA group (p&lt;0.01), Figure 1. Other relevant clinical, anatomic or laboratory predictors could not be found in multivariate Cox regression analysis.

Conclusion
The amount of left atrial LVA is a good predictor for arrhythmia recurrence, even in a cohort of repeat ablations with progressively diseased atria. EAM derived left atrial volume has minor impact on recurrence in this group and should not solely guide the decision in favor or against further invasive treatment. Accomplishing a thorough 3D map of the left atrium to account for LVA should be mandatory in all repeat procedures.Baseline CharacteristicsKaplan-Meier for recurrence and voltage
One-year effectiveness and safety outcomes of edoxaban treatment in Chinese patients with atrial fibrillation: First snapshot of more than 4,800 patients from the ETNA-AF-China study
Authors: Guo X Y , Du J , Yin Y H , Heng Q , Jia Z S , Ji X J , Zhang Y Q , Liang X , Deng B , Liu J Y , Yi Y , Liu M Q , Chen C , Unverdorben M , Ma C S 
Published: May 2024

Abstract

Background
Direct oral anticoagulants (DOACs) have become the first-line therapy for ischaemic stroke prevention in atrial fibrillation (AF) patients. Data on the effectiveness and safety of single DOAC in large Chinese populations are scarce.

Purpose
We firstly present the one-year outcome data of edoxaban treatment in 5001 Chinese AF patients.

Methods
This is a multi-centre, prospective, observational study, ETNA-AF-China, conducted in 89 centres from four economic regions in Mainland of China with a follow-up of two years. Primary endpoint of safety [bleeding events including intracranial hemorrhage (ICH), all-cause and cardiovascular (CV) mortality] and efficacy endpoints [stroke, systemic embolic events (SEE), transient ischemic attack (TIA)] were adjudicated. Annualised event rates and Kaplan­Meier (KM) survival curves are given.

Results
A total of 4822 patients (57.1% male) using edoxaban (60 mg OD: n=2614, 30 mg OD: n=2208) who completed one-year follow-up were included in the full analysis set. The mean (SD) age of the overall patient population was 70.3 (9.5) years, CHA2DS2-VASc and HAS-BLED scores were 2.9 (1.4), 1.7 (1.0), with creatinine clearance (CrCl) of 71.2 (27.7) mL/min. Patients receiving 30 mg OD edoxaban at baseline were older (73.4 vs 67.7 years), with higher CHA2DS2-VASc score (3.3 vs 2.6), larger percentage of frail (9.9% vs 3.4%), and higher renal impairment (defined as CrCl ≤80 mL/min, 70.3% vs 42.9%). Annualised rates for all-cause and cardiovascular death in the overall population were very low with 2.22%/year and 0.41%/year, respectively. (Figure 1) The death rates were nearly three times lower in those receiving standard dose (60 mg) than reduction dose (30 mg) of edoxaban. Annualised event rates for all stroke/SEE (1.03%/year) and ischemic stroke (0.60%/year) were similar between two dose groups. Overall, annualised rates for major bleeding (1.03%/year), ICH (0.18%/year), major gastrointestinal (GI) bleeding (0.48%/year) events were relatively low, and those on 60 mg dose experienced less above bleeding events. Cumulative survival analysis demonstrated a slow increase in time-to-first event curve of all-cause death; and from baseline to 1-year follow-up, significant lower events of all-cause death (log-rank p&lt;0.001), major bleeding (p=0.002) in 60 mg vs 30 mg edoxaban groups. (Figure 2).

Conclusion
Low incidences of major bleeding, notably ICH, major GI bleeding, and CV death were observed in unselected 4822 patients with AF during 1-year of edoxaban treatment. These findings confirm the effectiveness and safety of routine edoxaban use in China, consistent with other countries, and reinforce the results of the ENGAGE AF-TIMI 48 trial.Figure 1Figure 2
Effects of long-term continuous screening for atrial fibrillation on heart failure events - results from the randomized LOOP Study
Authors: Xing L Y , Hojberg S , Krieger D W , Graff C , Olesen M S , Healey J S , Mcintyre W F , Brandes A , Kober L , Haugan K J , Svendsen J H , Diederichsen S Z 
Published: May 2024

Abstract

Background
Previous research established a solid link between atrial fibrillation (AF) and heart failure (HF). However, while two landmark trials have assessed AF screening for stroke prevention, the potential impact of AF screening on HF remains unclear.

Purpose
This secondary analysis of the LOOP Study aimed to investigate the effects of AF screening on HF events.

Methods
The LOOP Study was a randomized clinical trial evaluating long-term continuous AF screening with implantable loop recorder (ILR) in individuals aged 70-90 years and with ≥1 of arterial hypertension, diabetes mellitus, HF, and/or prior stroke. At inclusion, study participants were randomized 1:3 to either ILR screening or usual care. Anticoagulation was recommended upon AF detection, whereas other treatment was left to the discretion of the treating physician. In this secondary analysis, a cause-specific Cox regression model was applied to explore the effects of AF screening vs usual care on 1) time-to-first HF event and 2) total HF events, with the latter performed using the Andersen-and-Gill extension. HF event was defined as newly diagnosed HF with left ventricular ejection fraction ≤40% or any HF hospitalization in participants with prior diagnosis of HF with reduced ejection fraction.

Results
In total, 6004 participants were enrolled in the LOOP Study: 1501 in the ILR group vs 4503 in the Control group. The study population had a mean age of 75 years and slightly more males than females (53% vs 47%), whereas 266 (4.4%) were previously diagnosed with HF at baseline. During a median follow-up of 5.4 years, a total of 208 HF events were reported in 175 (2.9%) participants: 37 events among 34 (2.3%) participants in the ILR group vs 171 events among 141 (3.1%) participants in the Control group. For time-to-first HF event, the annualized event rate was 0.44%/year [95% confidence interval (CI): 0.30-0.62] vs 0.61%/year [95% CI: 0.51-0.72] for ILR vs Control, corresponding to a hazard ratio (HR) of 0.72 [95% CI: 0.50-1.05]. When assessing total HF events, a significantly lower event rate was observed in the ILR group (0.47%/year [95% CI: 0.33-0.65]) compared with the Control group (0.73%/year [95% CI: 0.62-0.84]), resulting in a HR of 0.65 [95% CI: 0.44-0.97].

Conclusions
Among elderly individuals with additional stroke risk factors, long-term continuous AF screening led to a significantly reduced risk of total HF events, compared with usual care. This should be considered as hypothesis-generating and warrants further investigation.Cumulative incidence of HF event
Early rhythm control in patients with recently diagnosed atrial fibrillation: findings from the GLORIA-AF Registry Phase III
Authors: Corica B , Romiti G F , Proietti M , Mei D A , Boriani G , Ding W Y , Olshansky B , Huisman M V , Lip G Y H 
Published: May 2024

Abstract

Background
Early rhythm control (ERC) can improve outcomes in select patients with atrial fibrillation (AF) but real-world data are lacking.

Purpose
To evaluate the effectiveness of ERC in a real-world cohort of AF patients.

Methods
From the global, prospective GLORIA-AF Phase III Registry, adult patients with recent diagnosis (&lt; 3 months and &lt; 4.5 months in Latin America) of AF and CHA2DS2-VASc score ≥1 were included. ERC was defined as treatment with an antiarrhythmic drug, catheter ablation, or cardioversion at the baseline. Multivariable logistic regression analysis determined the odds of receiving ERC and an oral anticoagulant [OAC] with results reported as adjusted Odds Ratio (aOR) and 95% Confidence Intervals (95%CI). Risk of major outcomes was determined using multiple Cox regression analyses. The primary outcome was a composite of all-cause death and major adverse cardiovascular events (MACE). Secondary outcomes included all-cause death, thromboembolism and major bleeding. Results were reported as adjusted Hazard Ratio (aHR) and 95%CI.

Results
21,051 AF patients (age: 70.2±10.3, 45% female) were included. Of these, 6,932 (32.9%) received ERC, while 14,119 (67.1%) did not. Patients receiving ERC were younger with a higher prevalence of paroxysmal AF (62.8% vs. 53.2%) and heart failure (23.1% vs. 21.4%). They were less likely to have prior stroke/transient ischemic attack (TIA), chronic obstructive pulmonary disease (COPD), and they had a lower mean CHA2DS2-VASc score (3.0±1.5 vs. 3.3±1.5). Age ≥75 [aOR: 0.53; 95%CI (0.0.49-0.57)] and age 65-75 [aOR: 0.76; 95%CI (0.70-0.82)] were associated with lower odds of receiving ERC. Those with prior stroke/TIA [aOR: 0.55; 95%CI (0.50-0.61)] and COPD [aOR: 0.82; 95%CI (0.71-0.94)], as well as patients with more sustained form of AF and patients recruited in North America were less likely to receive ERC. Conversely, female sex, higher symptom burden, hypertension and coronary artery disease were associated with higher odds of receiving ERC (Figure 1). Patients who received ERC were more likely to receive OACs [aOR: 1.36; 95%CI (1.25-1.48)].
Survival curve for the primary outcome according to ERC are shown in Figure 2. During a median follow-up of 3.0 [IQR: 2.9-3.1] years, ERC was associated with lower risk of the primary composite outcome (aHR: 0.88, 95% CI:0.80-0.96, p=0.006); Similar results were observed for the secondary outcomes.

Conclusions
In a real-world population with recently diagnosed AF, clinical risk factors and characteristics were associated with ERC. Patients who received ERC had a reduced risk of major outcomes. These findings suggest that in real-world patients with AF, ERC may provide beneficial effects on long-term outcome.Odds Ratios to be treated with ERC.Survival curve.
The effect of amiodarone given periprocedurally on the effectiveness of catheter ablation in patients with persistent atrial fibrillation refractory to cardioversion
Authors: Ehrenhalt G , Ciszewski J , Farkowski M , Baranowski R , Rymuza H , Jedrzejczyk B , Jankowska A , Kowalik I , Maciag A , Syska P , Lewandowski M , Kolakowski K , Zalewska J , Pytkowski M 
Published: May 2024

Abstract

Background
Rhythm control strategy in patients with persistent atrial fibrillation refractory to electrical cardioversion (AF-REC) poses an important clinical problem. Little is known about the effect of amiodarone therapy given periprocedurally with catheter ablation on maintaining sinus rhythm in this group of patients.

Purpose
This study aimed to determine whether initial amiodarone therapy introduced prior to AF ablation and continued for one month after the procedure affects the long-term effectiveness of the rhythm control strategy in patients with AF-REC.

Methods
We conducted a retrospective case-control study of medical records of AF-REC patients treated periprocedurally with amiodarone in addition to pulmonary vein isolation. Data on comorbidities, transthoracic echocardiogram results, and short- and long-term effectiveness of ablation was extracted. Patients were followed up in the out patient clinic with the use of a 72-hour Holter monitoring and telephone interviews. AF recurrence was defined as ≥ 30s episode of atrial tachyarrhythmia.

Results
The analysis comprised 56 patients: 37 in the amiodarone and 19 in the control group; 12 women, mean age 57 years, mean follow-up of 39.5 months. Amiodarone was discontinued after 1 month at the most after the ablation in all of the patients. The primary endpoint (AF-free survival) was achieved in 17 (45,9%) pts in the amiodarone group and 3 (15,8%) pts in the control group (p=0.026). On multivariable analysis, amiodarone therapy was the only variable correlating with the primary endpoint: OR 6.8 (95% CI: 1.4 - 33.9), p=0.019. Conversion of AF from persistent to paroxysmal or no AF in the follow-up was achieved in 32 pts (86,5%) in the amiodarone group and 9 pts (47,4%) in the control group: OR 8.0 (95% CI: 2.1 - 30.0), p=0.002. Patients in the amiodarone group experienced a borderline better increase of left ventricular ejection fraction: ∆ 5.2% (95% CI: -0.1 - 10.5), p= 0.054.

Conclusion
Periprocedural use of amiodarone in patients ablated due to persistent atrial fibrillation refractory to electrical cardioversion may lead to significantly better long-term efficacy of catheter ablation in this group of patients.
J-curved phenomenon between the prevalence of left atrial low-voltage areas and body mass index existed in patients with atrial fibrillation ablation
Authors: Matsuda Y , Masuda M , Uematsu H , Sugino A , Ooka H , Kudo S , Fujii S , Asai M , Okamoto S , Ishihara T , Nanto K , Tsujimura T , Hata Y , Higashino N , Mano T 
Published: May 2024

Abstract

Background
Left atrial low-voltage areas (LVAs) were known to be associated with atrial fibrosis and atrial fibrillation (AF) recurrence after catheter ablation. However, the association between body mass index (BMI) and prevalence of LVAs has not been fully elucidated. We hypothesized that LVAs were more frequently found in patients with abnormal BMI than in those with normal BMI.

Purpose
The purpose of this study was to clarify the association between body mass index (BMI) and the prevalence of LVAs in patients with AF ablation.

Methods
Between December 2014 and March 2022, 1,479 (age, 68±10 years; female, 500 [34%]) consecutive patients who underwent initial AF ablation were enrolled. BMI was divided into four groups, namely &lt;18.5 kg/m², 18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m². LVAs was defined as areas with bipolar voltage of &lt;0.5 mV covered ≥5 cm² of left atrium. Rhythm outcome following the catheter ablation procedure was also followed for 24 months.

Results
LVAs were found in 349 (24%) patients. J-curved phenomenon existed between BMI and the prevalence of LVAs (Figure 1). In particular, BMI &lt;18.5 kg/m² was an independent predictor of LVAs on multivariate analysis (odds ratio, 1.9; 95% confidence interval: 1.01–3.5; p=0.046). As for rhythm outcome, there was significant difference in freedom from AF recurrence among groups stratified by BMI (Figure 2).

Conclusions
Between BMI and the prevalence of LVAs, J-curved phenomenon existed in patients with AF ablation. There was significant difference in rhythm outcome following AF ablation among groups stratified by BMI.Figure 1Figure 2
Efficacy of laser balloon left atrial roof ablation for patients with atrial fibrillation
Authors: Yamasaki T , Kakita K , Pak M , Hattori T 
Published: May 2024

Abstract

Background
The roof area ablation beyond pulmonary vein (PV) isolation (PVI) using a cryoballoon has been described as an effective therapy for patients with atrial fibrillation (AF). However, the effect of roof area ablation performed with a visually guided laser balloon (VGLB) remains to be elucidated.

Purpose
This study aims to investigate the efficacy of roof area ablation using VGLB.

Methods
A total of 325 patients with AF (paroxysmal AF=199, persistent AF=126) who underwent VGLB ablation from July 2018 to May 2022 were analyzed retrospectively. After initial circular isolation, VGLB was inflated to a larger size on both sides of superior PVs, and the isolation areas were extended to the roof portion. At the end of the procedure, left atrial (LA) voltage mapping was obtained to assess the LA roof scar area, and differential pacing was performed to confirm the complete conduction block. Our study population was divided into the PVI group (LB-PVI, n=228) and the roof line block beyond PVI group (LB-Roof, n=97). The efficacy endpoint was defined as freedom from atrial tachyarrhythmia (ATa) between months 3 and 12.

Results
One-year clinical follow-up could be obtained in 170 patients with LB-PVI and 81 patients with LB-Roof. The Kaplan-Meier survival curves are shown in Figure. At the end of the 12 months of follow-up, freedom from ATa was 80.8% in patients with LB-PVI and 91.2% in LB-Roof. The ATa freedom rate was significantly higher in the LB-Roof than in the LB-PVI (P=0.03).

Conclusion
The roof area ablation using VGLB was proved to be effective for patients with AF.The Kaplan-Meier survival curves